Abstract: [Objective]To detect the effect of Rosiglitazone on hepatic injury in patients with acute pancreatitis.[Methods]Ninety acute pancreatitis patients were enrolled in this study.Patients were divided into:control group(n=45)and Rosiglitazone observation group(n=45).ALT,AST,TNF-α,and IL-1 expression was detected by ELISA analysis.The clinical effect was compared.[Results]There was no significant difference in the levels of ALT,AST,TNF-α,and IL-1 expression between the two groups before treatment(P＞0.05).Five days after treatment,ALT,AST,TNF-α,and IL-1 expression was lower in observation group than that in control group(P＜0.05 and P＜0.01).Abdominal pain and abdominal distension recovery time,exhaust gas and defecation recovery time,temperature recovery time,and hospitalization time was 5.17±1.09 d,4.95±1.02 d,4.56±0.82 d,and 15.27±3.81 d in control group,which was significantly higher than that of 3.44±0.76 d,3.26±0.75 d,3.13±0.64 d,and 9.86±3.06 d in observation group(P＜0.05 and P＜0.01).The clinical effect rate in observation was 88.9%(40/45),which was higher than that of 71.1%(32/45)in control group(P＜0.05).[Conclusion]Rosiglitazone inhibits the inflammatory reaction to protect the hepatic injury in patients with acute pancreatitis,with significantly clinical effect.